Furthermore, PARP1‐inhibition via Olaparib resulted in the dissolution of the PRMT6/PARP1/CRL4B complex, and strengthening the circadian rhythm amplitude and inhibiting breast cancer progression. Here, PRMT6 is linked to breast cancer.